## THE GROWING RADIOPHARMACEUTICALS MARKET

## FROM THE BRACKEN GROUP



Companies: Lantheus, GE Healthcare

LICENSING

tumors

Product: Investigational radiohybridtargeted PSMA targets for prostate cancer **Acquirer:** Blue Earth

Indication: Treatment of Neuroendocrine

Company: Advanced Accelerator

**Licensee:** Scintomics

FDA APPROVAL

**Product:** Lutathera

Applications (Novartis)

LAUNCH

**Product: LYMPHOSEEK** (Tc 99m tilmanocept)

**Indication:** Lymph Node Solid Tumors

Company: Norgine B.V.

LAUNCH

01.19

**Product:** Illumet Microsite Kit (For the Preparation of 68Ga-PSMA)

**Indication:** Prostate Cancer **Company:** Telix Pharmaceuticals

LICENSING

**Product:** All FAPI precursor **Indication**: Oncology **Companies:** Sofie Biosciences with University of Heidelburg

MERGER

Companies: Jubilant Pharma Radiopharmaceutical Drug Development and Manufacturing + Jubilant Pharma Radio Pharmacy

New Entity: Jubilant Radiopharma

**ACQUISITION** 

**Acquirer:** Bracco Imaging **Acquired:** Blue Earth Diagnostics

**PARTNERSHIP** 

**Product:** GalliProst **Indication:** Prostate Cancer **Companies:** GE Healthcare

and Theragnostics

MERGER

**Companies:** Fuzionaire Diagnostics and Japan Medical Isotope Technology Development K.K.

New Entity: Fuzionaire Radioisotope Technologies K.K.

**ACQUISITION** 

**Acquirer**: Lantheus **Acquired:** Progenics

STRATEGIC COLLABORATION

**Companies:** Sofie Biosciences signs with ABX Advanced Biochemical Compounds GmbH for the production and distribution of all FAPI products

LICENSE AGREEMENT

**Product:** Flurpiridaz F 18 **Indication:** Coronary Artery Disease (CAD)

05.17

**ACQUISITION** 

**Acquirer:** Sofie Biosiences **Acquired:** Zevacor Pharma

FDA APPROVAL

Company: Advanced

**Accelerator Applications** 

FDA APPROVAL

**Product:** Axumin (Fluciclivine <sup>18</sup>F) **Indication:** Prostate Cancer **Company:** Blue Earth Diagnostics (now Bracco Imaging)

Product: NETSPOT: Gallium68 Dotatate Kit

**Indication:** Neuroendocrine Tumor Detection

**ACQUISITION Acquirer:** Novartis

**Acquired:** Advanced Accelerator

Applications for \$3.9B

2016

2018 2017

2019